Dr. Cercek on Chemotherapy Resistance in dMMR Rectal Cancer

Video

In Partnership With:

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient rectal cancer.

Andrea Cercek, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses chemotherapy resistance in mismatch repair deficient (dMMR) rectal cancer.

Locally advanced rectal cancer is typically treated with a tri-modality therapy; this approach includes chemoradiation, surgery, and chemotherapy. It was recently discovered that moving 5-fluorouracil and oxaliplatin-based chemotherapy upfront, and following with chemoradiation and surgery can improve patient compliance with chemotherapy. This compliance, Cercek says, theoretically improves the treatment of micrometastatic disease as well as rates of complete response. This approach has now been incorporated into the guidelines as the standard of care for patients with locally advanced rectal cancer in the United States.

However, it was discovered that patients with dMMR or microsatellite instability-high rectal cancer did not respond well to chemotherapy upfront, he adds. Given this anecdotal evidence, investigators initiated a study to evaluate the sensitivity of dMMR rectal cancer to chemotherapy. In the study, the baseline characteristics, treatment modalities, and clinical outcomes of patients with dMMR rectal cancer were retrospectively reviewed.

Related Videos
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD